Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06200597 · ClinicalTrials.gov registry record · Phase 1
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects
A Phase 1 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT06200597: Completed Phase 1 study, sponsored by Almirall, S.A..
NCT06200597 is a Phase 1 study that has completed, run by Almirall, S.A.. The registered enrollment target is 92 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06200597, a Phase 1 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.
Interventions
- OTHER Placebo
- DRUG LAD603
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2025-05-29 |
| Phase | Phase 1 |
What the finished NCT06200597 record still lists
NCT06200597 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06200597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06200597 about?
NCT06200597 is a clinical study titled "A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects". The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.
What is the current status of trial NCT06200597?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2023-12-05. Estimated completion is 2025-05-29.
What interventions are being tested in trial NCT06200597?
The interventions under investigation include: Placebo (OTHER), LAD603 (DRUG).
Who is sponsoring clinical trial NCT06200597?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06200597's enrollment target sits among peer trials
92 625th of 2000 higher than 1,375 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI